Zimmermann, Iwan http://orcid.org/0000-0003-3476-4749
Egloff, Pascal
Hutter, Cedric A. J. http://orcid.org/0000-0002-8920-3343
Kuhn, Benedikt T. http://orcid.org/0000-0002-5406-7994
Bräuer, Philipp http://orcid.org/0000-0003-4127-2638
Newstead, Simon http://orcid.org/0000-0001-7432-2270
Dawson, Roger J. P.
Geertsma, Eric R. http://orcid.org/0000-0002-2789-5444
Seeger, Markus A. http://orcid.org/0000-0003-1761-8571
Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (PP00P3_144823)
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (407240_177368)
Kommission für Technologie und Innovation (16003.1 PFLS-LS)
Cluster of Excellence Frankfurt (Macromolecular Complexes) CRC807
BioEntrepreneur-Fellowship of the University of Zurich
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (20B1-1_175192)
Wellcome Trust (102890/Z/13/Z)
Article History
Received: 3 September 2019
Accepted: 16 January 2020
First Online: 8 April 2020
Competing interests
: The authors declare competing financial interests. I.Z., P.E., R.J.P.D. and M.A.S. are co-founders and shareholders of Linkster Therapeutics AG.